Relay Therapeutics, Inc. (RLAY) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RLAY Revenue Growth
RLAY Revenue Analysis (2018–2025)
As of May 6, 2026, Relay Therapeutics, Inc. (RLAY) generated trailing twelve-month (TTM) revenue of $10.7 million, reflecting significant decline in growth of -60.9% year-over-year. The most recent quarter (Q1 2026) recorded $3.0 million in revenue, down 57.1% sequentially.
Looking at the longer-term picture, RLAY's 5-year compound annual growth rate (CAGR) stands at -28.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $82.7 million in 2020.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), ARVN (-0.3% YoY), and MRUS (+55.9% YoY), RLAY has underperformed the peer group in terms of revenue growth. Compare RLAY vs KYMR →
RLAY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RLAYCurrent | $11M | -60.9% | -28.6% | -1971.6% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 MRUS | $35M | +55.9% | +4.7% | -753.0% |
RLAY Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $15.4M | +53.4% | $11.8M | 76.8% | $-302,738,000 | -1971.6% |
| 2024 | $10.0M | -60.8% | $10.0M | 100.0% | $-372,468,000 | -3722.1% |
| 2023 | $25.5M | +1749.8% | $25.5M | 100.0% | $-373,000,000 | -1460.1% |
| 2022 | $1.4M | -54.4% | $1.4M | 100.0% | $-299,275,000 | -21670.9% |
| 2021 | $3.0M | -96.3% | $3.0M | 100.0% | $-364,698,000 | -12040.2% |
| 2020 | $82.7M | - | $79.1M | 95.7% | $-55,796,000 | -67.5% |
| 2019 | $0 | - | $-2,845,000 | - | $-84,048,000 | - |
| 2018 | $0 | - | $-2,154,000 | - | $-49,889,000 | - |
See RLAY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLAY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RLAY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRLAY — Frequently Asked Questions
Quick answers to the most common questions about buying RLAY stock.
Is RLAY's revenue growth accelerating or slowing?
RLAY revenue declined -60.9% year-over-year, contrasting with the 5-year CAGR of -28.6%. TTM revenue fell to $11M. This reverses the prior growth trend.
What is RLAY's long-term revenue growth rate?
Relay Therapeutics, Inc.'s 5-year revenue CAGR of -28.6% reflects the variable expansion pattern. Current YoY growth of -60.9% is below this long-term average.
How is RLAY's revenue distributed by segment?
RLAY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.